MIRA INFORM REPORT

 

 

Report Date :

11.09.2013

 

IDENTIFICATION DETAILS

 

Name :

DENVER FARMA S.A.

 

 

Registered Office :

Esmeralda 1066, 2o."G", (1099), Buenos Aires City, Repúblic

 

 

Country :

Argentina

 

 

Financials (as on) :

30.06.2012

 

 

Date of Incorporation :

21.09.1988

 

 

Legal Form :

Limited company

 

 

Line of Business :

Medical Specialties, Processing,  Marketing

 

 

No. of Employees :

88

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

Payment Behaviour :

Slow but correct

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

Argentina

B1

B1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

ARGENTINA - ECONOMIC OVERVIEW

 

Argentina benefits from rich natural resources, a highly literate population, an export-oriented agricultural sector, and a diversified industrial base. Although one of the world's wealthiest countries 100 years ago, Argentina suffered during most of the 20th century from recurring economic crises, persistent fiscal and current account deficits, high inflation, mounting external debt, and capital flight. A severe depression, growing public and external indebtedness, and an unprecedented bank run culminated in 2001 in the most serious economic, social, and political crisis in the country's turbulent history. Interim President Adolfo RODRIGUEZ SAA declared a default - at the time the largest ever - on the government's foreign debt in December of that year, and abruptly resigned only a few days after taking office. His successor, Eduardo DUHALDE, announced an end to the peso's decade-long 1-to-1 peg to the US dollar in early 2002. The economy bottomed out that year, with real GDP 18% smaller than in 1998 and almost 60% of Argentines under the poverty line. Real GDP rebounded to grow by an average 8.5% annually over the subsequent six years, taking advantage of previously idled industrial capacity and labor, an audacious debt restructuring and reduced debt burden, excellent international financial conditions, and expansionary monetary and fiscal policies. Inflation also increased, however, during the administration of President Nestor KIRCHNER, which responded with price restraints on businesses, as well as export taxes and restraints, and beginning in 2007, with understating inflation data. Cristina FERNANDEZ DE KIRCHNER succeeded her husband as President in late 2007, and the rapid economic growth of previous years began to slow sharply the following year as government policies held back exports and the world economy fell into recession. The economy in 2010 rebounded strongly from the 2009 recession, but has slowed since late 2011 even as the government continued to rely on expansionary fiscal and monetary policies, which have kept inflation in the double digits. The government expanded state intervention in the economy throughout 2012. In May the Congress approved the nationalization of the oil company YPF from Spain's Repsol. The government expanded formal and informal measures to restrict imports during the year, including a requirement for pre-registration and pre-approval of all imports. In July the government also further tightened currency controls in an effort to bolster foreign reserves and stem capital flight.

Source : CIA


Registered Name   

 

DENVER FARMA S.A.

CUIT No.: 33-62928265-9

 

 

Summary      

 

BEGINNER OF ACTIVITIES, INCORPORATED IN 1988. BALANCE SHEET AT 30/06/2012. NO REGISTRA ITS ADVERSE CREDIT HISTORY. FIT FOR NEW MODERATE CREDITS WITH GUARANTEE.

 

 

Operations       

 

MEDICAL SPECIALTIES
PROCESSING
MARKETING

 

 

Legal Structure   

 

Legal form:                     Limited company
Created:                          21/09/1988
Insc.R.P.de Commerce:   04/10/1988 No.6938,Lo.105,ToA
I.G.P.J.: Register No.:      122.637
Duratión:                         04/10/2087
End of fiscal year:           June 30
Afip Nro:                         56 de Avda del Libertador 1436 de Vicente Lopez

 

 

Contact       

 

Legal Address: Esmeralda 1066, 2o."G", (1099), Buenos Aires City, Repúblic Argentina.

Operative Address and Administrative: Natalio Querido 2285, Munro (1603), Buenos Aires, Repúblic Argentina.

Tel.: (54-011) 4756-5436/5295
Fax.: (54-011) 4762-3425
E-mail: abastecimiento@denverfarma.com.ar

 


 

Partners     

 

President:            AQUILES ESTEBAN ROSSI
V.President:         JOSE LUIS TOMBAZZI

Directors:            MABEL TERESA ROSSI
                           LUCAS ESTEBAN ROSSI

Alternates:           LUCIANO JOSE TOMBAZZI
                            MARCELA MABEL TOMBAZZI

Using of signature: President and Vicepresident.
 

 

Corporate Stock       

 

The share capital of the company is set to the sum of $ 300,000, represented by the same amount of ordinary bearer shares one vote each, v/n., $ 1,00.-

 

 

Personal Information 

 

ROSSI AQUILES ESTEBAN:

argentino, married, 07/01/1951, DNI.No. 8.402.304 (CUIT No.20-08402304-4) address in Larrumbe 12, 2do."C", Martínez, Province Buenos Aires.

TOMBAZZI JOSE LUIS:

argentino, married, 19/08/1954, DNI.No. 11.217.282 (CUIT No.20-11217282-4) address in Asunción 4514, 3er.piso, Buenos Aires City.

Registered in DROGUERIA GENERAL S.A.

 

 

History 

 

n 1988 and in order to tackle the exploitation of the activities being developed, has been legally established business owner who, for the purposes intended, it is established at the addresses set out in due course.

It is our understanding that it is an integral part of any economic group or their managers participate alongside in any company other than the already mentioned is timely.

 

 

 

Economic-Financial Position   

 

 

BALANCE SHEET AT 30/06/2011 AND 30/06/2012, EXPRESSED IN PESOS ARGENTINOS, EXCHANGE: 1 DOLAR = $ 5,60.-
                                    30.06.2011        30.06.2012
                                    ----------        -----------

CASH INVESTMENTS, CREDITS           24.670.103        40.077.329
INVENTORIES                         12.732.825        16.444.605

TOTAL ASSETS CURRENT                37.402.928        56.521.934
ASSETS NON-CURRENT                  20.417.504        21.156.003

TOTAL ASSETS                        57.820.432        77.677.937

DEBTS                               20.912.728        28.701.253
SALARIES AND SOCIAL CHARGES         2.051.657         3.233.820
LIABILITIES CURRENT                 22.964.385        31.935.073
LIABILITIES NON-CURRENT                   -           1.688.571      
TOTAL LIABILITIES                   22.964.385        33.623.644
NET WORTH                           34.856.047        44.054.293
TOTAL GENERAL                       57.820.432        77.677.937

VENTAS NETAS                        76.818.160        118.518.030
COSTO DE VENTAS                     -40.938.592       - 68.364.964
GANANCIA BRUTA                      35.879.568        50.153.066
DEBTS COMERCIALIZATION              -16.371.853       - 23.946.012
SUB TOTAL                           11.819.584        15.801.791
OTROS INCOMES AND EXPENSES          - 3.953.287       -3.953.545
FINAL RESULT                        7.866.297         11.848.246

 

 

Assets     

 

BUILDINGS:
---------
The fixed assets of the company are occupied property in their efforts which, taken together, have significant market value.

 

 

Evolution and Results       

 

Basically is dedicated to the development and commercialization of drugs essentially treating the production of generics.

It has modern production units covering a broad spectrum of dosage forms with procedures validated by the World Health Organization.

Its lines are represented by generic set out:

* Allergy                        * Anesthesia
* Anxiolytics                  * flu
* Antiosteoporotic         * Wormers
* Antisepsis                  * Cardiology
* Dermatology               * Diabetology
* Pain/Inflammation                   * Gastroenterology
* Gynecology                * Ear drops
* Infectious                   * Neurology
* Contrast Media           * Nutrition
* Ophthalmology                       * Psychiatry
* respiratory tract           * Various

Concrete imports among other countries from Switzerland, China and India among other countries, not being marked its foray into the export market.

* 88 EMPLOYEES

FOREIGN TRADE:
--------------
In the last twelve months it has carried out imports for a total value of u$s. 2.577.477 from:

INDIA..........................              U$S 863.685
SWIZERLAND.....................      U$S 777.358
URUGUAY........................        U$S 368.528
OTHERS COUNTRIES...............U$S 568.906

Among the company the following brands:

ALAGER                       ALIAPRES
ANZOLDEN                  BOLONA
PANCLOFLEX               PARCETIN
SENTUL                        STILENCIL
TYLOFORMIN               ZOLATIDEN
CLOTRIDEN                  DENVER BIO
DORTIDEN                   GLAUCODEN
MIFEPIL                        OFTALOOK
OTOBIOTIC                   PANCLOBIOTIC

 

 

Branches     

 

Industrial plant: Centro Industrial Garin, Escobar, Buenos Aires.

 

 

 

 

Payment Record and Credit Risk      

 

Banks:
------
BANCO DE GALICIA Y BS.AIRES S.A.     Munro

Credit Risk:
------------
JUNE 2013

BANCO PROVINCIA DE BUENOS AIRES........ $  2.448.000
BANCO DE GALICIA  Y BUENOS AIRES.......   $  1.681.500
AMERICAN EXPRESS.......................                $    247.400

SITUATION 1: NORMAL COMPLIANCE

INSURANCE:
----------
LIBERTY S.A.

 

 

Concept       

 

It doesn't register that could affect its commercial concept.

According to our consultations, it complies in due time the commitments taken and has a good concept.

* FULFILLMENT: WITHOUT OBJECTIONS

 

 

Final Opinion    

 

We consider feasible the credit treatment with this company by moderate amounts.

For higher amounts, we suggest taking appropriate guarantees.

* FIT FOR NEW MODERATE CREDITS


FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.64.22

UK Pound

1

Rs.100.83

Euro

1

Rs.85.21

 

 

INFORMATION DETAILS

 

Report Prepared by :

NIS

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.